potential cancer risk for Protopic (tacrolimus) and Elidel (pimecrolimus)

There's now concern about a potential cancer risk for Protopic (tacrolimus) and Elidel (pimecrolimus).

FDA is adding a black box warning...and will soon require you to give a Medication Guide to patients getting these drugs.

It's NOT known for sure if these drugs increase cancer risk.

Practical advice for a better career, with unlimited access to CE

Pharmacy Technician's Letter includes:

  • 12 issues every year, with brief articles about new meds and hot topics
  • 200+ CE courses, including the popular CE-in-the-Letter
  • Helpful, in-depth Technician Tutorials
  • Access to the entire archive

Already a subscriber? Log in

Volume pricing available. Get a quote